An observational study in GI Bleeding, Perforation Colon and Perforation Bowel, sponsored by AdventHealth. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by AdventHealth · Observational
This study is designed as a multicenter prospective data recording study to document the performance of the DAT clip as part of standard medical care of patients. No experimental interventions will be performed.
Endoscopic clipping devices are instruments designed to achieve tissue approximation during gastrointestinal endoscopy. Although endoscopic clips were initially developed for the primary purposes of accomplishing hemostasis of focal gastrointestinal bleeding, the indications for endoscopic clipping have expanded to include closure of perforations and fistulas, securing positioning of catheters and stents as well as to provide a radio-opaque markers to direct endoscopic, radiological, and surgical therapy.
Traditionally, through-the-scope (TTS) clipping devices consist of 2 main components: metallic double pronged clips and delivery/deployment catheter-handle assembly. TTS clips are the most used devices for both hemostasis and defect closure given the familiarity and ease of use. However, larger defects or those in a difficult position within the GI tract can be difficult to close using conventional TTS clips alone, given the inherent restrictions in clip opening width and inability to approximate large gaps firmly and securely. Incomplete closure can have serious consequences, including delayed bleeding and need for additional interventions including surgery for treatment of acute perforations.
The Dual Action Tissue (DAT) clip is a novel, Federal Drug and Administration (FDA) approved commercially available 3-arm TTS clip designed for endoscopic closure of large defects. Compared to conventional TTS clips, the DAT clip has an additional center post or fixed column in the middle position. The two arms of the DAT clip operate independent of each other, with an overall maximum opening width angle of 60 degrees. Opening and closing of each arm is controlled by two color-coded handles, which facilitates distinguishment of the clip arms during operation. The arm on one side of the DAT clip is opened to clamp the edge of a defect. The clamped mucosa can then be pulled close to the other side of the defect. The second arm of the DAT is then opened to clamp the opposite edge. Once both edges of the defect are secured by the arms of the DAT clip, the clip can then be deployed by firmly pressing and releasing both handles simultaneously.
Experimental studies using the DAT clip have confirmed its safety and efficacy and shown it to be easy to operate, safe and effective for defect closure. Our initial experience in 6 cases (unpublished data) supports its safety and its utility as an additional endoscopic tool in our armamentarium for challenging tissue approximation. However, more data is needed to evaluate the performance and the role of the DAT clip. The purpose of this study is to prospectively evaluate our experience with the DAT clip as part of routine medical care.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
This study's planned enrollment of 250 is above the median of 176 across 117 observational studies indexed under Gastrointestinal Hemorrhage.
Browse Gastrointestinal Hemorrhage studies →AdventHealth is the lead sponsor of 113 studies on the registry; 22 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients scheduled to undergo endoscopic procedures at participating centers as medically indicated will be considered for the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treatment of bleeding Treatment of perforation and/or fistulas Tissue approximation for mucosal gaps associated with endoscopic resection (e.g., endoscopic mucosal resection, endoscopic submucosal dissection) or third space endoscopy (e.g., peroral endoscopic myotomy in the gastrointestinal tract)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
Complete closure rate.
Cases in which complete tissue approximation is achieved with the use of the DAT clip- no substantial gaps are visible in the closure line.
Time frame: 12 months
Rate of Achievement of intended targeted therapy.
Defined as cases in which utilization of the DAT clip accomplished the intended treatment effect (e.g., hemostasis, perforation closure)
Time frame: 12 months
Procedural time.
Measure of procedural time associated with the operation of the DAT clip for its intended purpose.
Time frame: 12 months
Adverse Events
Measured based on the rate of adverse events with the procedure.
Time frame: 12 months
Plan to share: No
Started Aug 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.
Of 42 non-industry observational studies under Gastrointestinal Hemorrhage, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 60 months is above that.
Counting every sponsor, half of 47 studies reached it within 36 months; a quarter within 23 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.